Supramolecular magnetonanohybrids for multimodal targeted therapy of triple-negative breast cancer cells
- 17 June 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 8 (32) , 7166-7188
Abstract
Despite the undeniable advances in recent decades, cancer remains one of the deadliest diseases of the current millennium, where the triple-negative breast cancer (TNBC) is very aggressive, extremely metastatic, and resistant to conventional chemotherapy. The nanotheranostic approach focusing on targeting membrane receptors often expressed at abnormal levels by cancer cells can be a strategic weapon for fighting malignant tumors. Herein, we introduced a novel “all-in-one nanosoldier” made of colloidal hybrid nanostructures, which were designed for simultaneously targeting, imaging, and killing TNBC cells. These nanohybrids comprised four distinct components: (a) superparamagnetic iron oxide nanoparticles, as bi-functional nanomaterials for inducing ferroptosis via inorganic nanozyme-mediated catalysis and magnetotherapy by hyperthermia treatment; (b) carboxymethyl cellulose biopolymer, as a water-soluble capping macromolecule; (c) folic acid, as the membranotopic vector for targeting folate receptors; (d) and doxorubicin (DOX) drug for chemotherapy. The results demonstrated that this novel strategy was highly effective for targeting and killing TNBC cells in vitro, expressing high levels of folate membrane-receptors. The results evidenced that three integrated mechanisms triggered the deaths of the cancer cells in vitro: (a) ferroptosis, by magnetite nanoparticles inducing a Fenton-like reaction; (b) magneto-hyperthermia effect by generating heat under an alternate magnetic field; and (c) chemotherapy, through the DOX intracellular release causing DNA dysfunction. This “all-in-one nanosoldier” strategy offers a vast realm of prospective alternatives for attacking cancer cells, combining multimodal therapy and the delivery of therapeutic agents to diseased sites and preserving healthy cells, which is one of the most critical clinical challenges faced in fighting drug-resistant breast cancers.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (PNPD, PROINFRA2010–2014)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (PQ1A-303893/2018-4, UNIVERSAL-457537/2014-0, 421312/2018-1, PIBIC-2017/2018/2019)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (PPM-00760-16, UNIVERSAL-APQ-00291-18)
- Pró-Reitoria de Pesquisa, Universidade Federal de Minas Gerais (PIBIC/PROBIC/PRPq-Editais)
- Financiadora de Estudos e Projetos (CTINFRA-PROINFRA 2008/2010/2011/2018)
This publication has 68 references indexed in Scilit:
- Helical poly(arginine) mimics with superior cell-penetrating and molecular transporting propertiesChemical Science, 2013
- Structural basis for molecular recognition of folic acid by folate receptorsNature, 2013
- A review of polysaccharide cytotoxic drug conjugates for cancer therapyCarbohydrate Polymers, 2013
- Polymeric Conjugates for Drug DeliveryChemistry of Materials, 2012
- Assessing the In Vitro and In Vivo Toxicity of Superparamagnetic Iron Oxide NanoparticlesChemical Reviews, 2011
- Doxorubicin as a Molecular Nanotheranostic Agent: Effect of Doxorubicin Encapsulation in Micelles or Nanoemulsions on the Ultrasound-Mediated Intracellular Delivery and Nuclear TraffickingMolecular Pharmaceutics, 2010
- FT‐IR, Raman, RRS measurements and DFT calculation for doxorubicinMicroscopy Research and Technique, 2010
- Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuationBMC Cancer, 2008
- The folate receptor: What does it promise in tissue-targeted therapeutics?Cancer and Metastasis Reviews, 2007
- Polymer conjugates as anticancer nanomedicinesNature Reviews Cancer, 2006